245 related articles for article (PubMed ID: 26926668)
1. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
[TBL] [Abstract][Full Text] [Related]
2. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
Ermer J; Corcoran M; Lasseter K; Martin PT
Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
Krishnan SM; Pennick M; Stark JG
Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
7. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Haffey MB; Buckwalter M; Zhang P; Homolka R; Martin P; Lasseter KC; Ermer JC
Postgrad Med; 2009 Sep; 121(5):11-9. PubMed ID: 19820270
[TBL] [Abstract][Full Text] [Related]
8. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.
Ermer J; Haffey MB; Richards C; Lasseter K; Roesch B; Purkayastha J; Corcoran M; Harlin B; Martin P
Clin Drug Investig; 2013 Apr; 33(4):243-54. PubMed ID: 23512639
[TBL] [Abstract][Full Text] [Related]
9. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Martin P; Dirks B; Gertsik L; Walling D; Stevenson A; Corcoran M; Raychaudhuri A; Ermer J
J Clin Psychopharmacol; 2014 Dec; 34(6):682-9. PubMed ID: 25310201
[TBL] [Abstract][Full Text] [Related]
11. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
[TBL] [Abstract][Full Text] [Related]
12. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
13. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
Krishnan SM; Stark JG
Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Ermer J; Corcoran M; Martin P
Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine.
Comiran E; Carlos G; Barreto F; Pechanksy F; Fröehlich PE; Limberger RP
Biopharm Drug Dispos; 2021 Jan; 42(1):3-11. PubMed ID: 33119133
[TBL] [Abstract][Full Text] [Related]
19. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
Ward K; Citrome L
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
